Supplies equipment and expendable materials to the biopharmaceutical industry. Provides solutions for cell culture growth media, cell lines, and bioreactor systems. Now — the numbers.
This is an established company with proven profits.
The gap is $2.5B. In times of high interest rates, a gap like that can squeeze a company.
The market pays 69.4× for every dollar this company earns in a year — a price that already assumes things go well.
No analyst target is on record for this company.
angles, checked one by one.
The 4 that stand out are on screen; the rest came back neutral.
The council scores out of 10; report-card grades are out of 100.
R&D Investment: Spending on future research is low.
An investor who bought at the very peak is down 61% today. The business is the same; what changed most is the price — and the expectations — the market pins on it.
It pays out $0.80 per share each year — regular cash for whoever holds the stock.
Over the last 4 years, sales grew only 1% a year on average. At this size, speeding back up is not easy.
The company’s market value is 69 times its annual profit. Even a small disappointment could hit the price hard.
No score published: this stock trades under $10,000 on a typical day, so the price beside it is not one you could reliably act on.
One-line summary: few numbers, an untested story. Keep watching.
Not covered, because the filings we hold do not carry it: the revenue breakdown.